High Tide Reports Strong Q2 Results with Record Revenue
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: PRnewswire
- Record Revenue: High Tide's German medical cannabis subsidiary, Remexian Pharma GmbH, achieved record revenue of $31.6 million in Q2 2026, demonstrating strong growth potential in the medical cannabis market and further solidifying its market position.
- Margin Improvement: Remexian's gross margins increased to 27%, reflecting effective cost control and successful strategies in product pricing and market demand, thereby enhancing overall profitability.
- Positive Free Cash Flow: The company reported positive free cash flow, indicating strong operational efficiency and financial health, which provides funding support for future expansions and investments, boosting investor confidence.
- Financial Transparency: High Tide released unaudited financial statements for the period ending April 30, 2026, ensuring financial transparency and enhancing market trust in its long-term growth strategy.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HITI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HITI
Wall Street analysts forecast HITI stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.310
Low
7.50
Averages
7.50
High
7.50
Current: 2.310
Low
7.50
Averages
7.50
High
7.50
About HITI
High Tide Inc. is a retail-focused cannabis company. The Company’s segments include bricks-and-mortar, e-commerce and medical cannabis distribution. Its Bricks-and-mortar segment includes the Company’s Canadian bricks-and-mortar locations. Its E-commerce segment includes the Company’s United States and international subsidiaries and supports the distribution of accessories and other items to the United States. The medical cannabis distribution segment includes the medical cannabis distribution operations. It offers a suite of proprietary brands which include Dopezilla, Atomik, Puff Puff Pass, Vodka Glass, Queen of Bud, and Cabana Cannabis Co. Canna Cabana is the Company’s primary retail cannabis business, offering the retail sale of various cannabis products and accessories through its provincially authorized cannabis retail store locations. Canna Cabana operates a retail cannabis chain with approximately 219 branded stores operating across Canada.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
High Tide Scheduled to Announce Q2 Earnings on June 15
- Earnings Announcement Date: High Tide (HITI) is set to release its Q2 earnings on June 15 after market close, with a consensus EPS estimate of -$0.02, reflecting a 50% year-over-year improvement, indicating potential for enhanced profitability.
- Revenue Expectations: The anticipated revenue for Q2 is $125.53 million, representing an 8.9% year-over-year decline, which highlights the volatility in the cannabis sector that may exert pressure on the company's performance and investor confidence.
- Historical Performance Review: Over the past two years, High Tide has only beaten EPS estimates 25% of the time, yet has surpassed revenue estimates 100% of the time, demonstrating stability in revenue growth despite the need for improvement in profitability metrics.
- Industry Context: While High Tide shows strong revenue growth, the overall volatility in the cannabis industry remains a significant risk factor that could impact future performance and investor decision-making.
See More
High Tide Reports Strong Q2 Results with Record Revenue
- Record Revenue: High Tide's German medical cannabis subsidiary, Remexian Pharma GmbH, achieved record revenue of $31.6 million in Q2 2026, demonstrating strong growth potential in the medical cannabis market and further solidifying its market position.
- Margin Improvement: Remexian's gross margins increased to 27%, reflecting effective cost control and successful strategies in product pricing and market demand, thereby enhancing overall profitability.
- Positive Free Cash Flow: The company reported positive free cash flow, indicating strong operational efficiency and financial health, which provides funding support for future expansions and investments, boosting investor confidence.
- Financial Transparency: High Tide released unaudited financial statements for the period ending April 30, 2026, ensuring financial transparency and enhancing market trust in its long-term growth strategy.
See More
High Tide Reports Record Revenue and Growth in Q2 2026
- Record Revenue: High Tide achieved a record revenue of CAD 179.3 million in Q2 2026, reflecting a 30% year-over-year increase, marking the fastest growth rate in 11 quarters and demonstrating strong performance in both Canadian and German markets.
- Medical Cannabis Growth: Remexian Pharma GmbH generated record revenue of CAD 31.6 million from medical cannabis sales in Germany, with gross margins increasing to 27%, indicating that the company's market share has now exceeded 14%, laying a solid foundation for future expansion.
- Positive Free Cash Flow: Although free cash flow was CAD 1.5 million, down from CAD 4.9 million last year, the company reported strong operating cash flow of CAD 8.8 million, showcasing its ongoing financial health and growth potential.
- Significant Membership Growth: Cabana Club membership has surpassed 2.65 million, up 39% year-over-year, while ELITE membership reached 178,000, an 84% increase, indicating continued improvement in customer loyalty and market share.
See More
High Tide Reports Strong Q2 Earnings Growth
- Earnings Performance: High Tide reported a non-GAAP EPS of C$0.01 for Q2, indicating a slight improvement in profitability despite the overall turbulent market conditions.
- Revenue Growth: The company achieved revenues of C$179.3 million, reflecting a robust year-over-year increase of 30.1%, showcasing its strong performance in the competitive Canadian cannabis market.
- Cash Position: As of April 30, 2026, High Tide's cash and cash equivalents totaled C$36.5 million, up from C$34.7 million in the prior year, indicating improved financial management.
- Market Challenges: Despite significant revenue growth, the volatility in the cannabis sector remains a concern, necessitating High Tide to navigate market uncertainties to sustain its growth momentum.
See More
High Tide Secures C$40 Million Loan Agreement with BMO
- Loan Agreement Secured: High Tide Inc. has secured a loan agreement with Bank of Montreal for C$40 million in new senior secured credit facilities, with closing expected within 30 days, marking a pivotal moment for the company's growth trajectory.
- Lower Capital Costs: The new credit facilities will replace the existing senior credit facility, which is anticipated to materially lower capital costs, thereby enhancing the company's financial flexibility and supporting future expansion plans.
- Market Share Growth: High Tide's subsidiary, Canna Cabana, operates 228 locations in Canada, capturing a 12% market share, and this financing will facilitate further expansion in global markets, particularly in its retail presence in Germany.
- Recognition of Sustained Growth: High Tide has been recognized as one of Canada's Top Growing Companies for five consecutive years, reflecting its strong performance and market leadership in the rapidly evolving cannabis industry, which is likely to continue attracting investor interest.
See More
High Tide Acquires Northern Helm to Expand Retail Operations
- Acquisition Details: High Tide is acquiring four retail stores from Northern Helm for $7.74 million, which will increase its total store count in Ontario to 103, thereby enhancing its market share and driving revenue growth.
- Strategic Objective: This acquisition represents a significant step towards High Tide's long-term goal of building a network of over 350 stores, demonstrating its commitment and capability in retail market expansion.
- Financial Impact: The purchase price reflects 4.5 times the annualized Adjusted EBITDA of the stores, indicating that High Tide is acquiring cash-flowing assets at reasonable multiples, which is expected to create long-term value for shareholders.
- Diversified Growth: High Tide's medical cannabis division is rapidly emerging as a second engine of growth, further solidifying its competitive advantage in the cannabis industry and driving sustainable growth across its overall business.
See More
High Tide Scheduled to Announce Q2 Earnings on June 15
- Earnings Announcement Date: High Tide (HITI) is set to release its Q2 earnings on June 15 after market close, with a consensus EPS estimate of -$0.02, reflecting a 50% year-over-year improvement, indicating potential for enhanced profitability.
- Revenue Expectations: The anticipated revenue for Q2 is $125.53 million, representing an 8.9% year-over-year decline, which highlights the volatility in the cannabis sector that may exert pressure on the company's performance and investor confidence.
- Historical Performance Review: Over the past two years, High Tide has only beaten EPS estimates 25% of the time, yet has surpassed revenue estimates 100% of the time, demonstrating stability in revenue growth despite the need for improvement in profitability metrics.
- Industry Context: While High Tide shows strong revenue growth, the overall volatility in the cannabis industry remains a significant risk factor that could impact future performance and investor decision-making.
See More
High Tide Reports Strong Q2 Results with Record Revenue
- Record Revenue: High Tide's German medical cannabis subsidiary, Remexian Pharma GmbH, achieved record revenue of $31.6 million in Q2 2026, demonstrating strong growth potential in the medical cannabis market and further solidifying its market position.
- Margin Improvement: Remexian's gross margins increased to 27%, reflecting effective cost control and successful strategies in product pricing and market demand, thereby enhancing overall profitability.
- Positive Free Cash Flow: The company reported positive free cash flow, indicating strong operational efficiency and financial health, which provides funding support for future expansions and investments, boosting investor confidence.
- Financial Transparency: High Tide released unaudited financial statements for the period ending April 30, 2026, ensuring financial transparency and enhancing market trust in its long-term growth strategy.
See More
High Tide Reports Record Revenue and Growth in Q2 2026
- Record Revenue: High Tide achieved a record revenue of CAD 179.3 million in Q2 2026, reflecting a 30% year-over-year increase, marking the fastest growth rate in 11 quarters and demonstrating strong performance in both Canadian and German markets.
- Medical Cannabis Growth: Remexian Pharma GmbH generated record revenue of CAD 31.6 million from medical cannabis sales in Germany, with gross margins increasing to 27%, indicating that the company's market share has now exceeded 14%, laying a solid foundation for future expansion.
- Positive Free Cash Flow: Although free cash flow was CAD 1.5 million, down from CAD 4.9 million last year, the company reported strong operating cash flow of CAD 8.8 million, showcasing its ongoing financial health and growth potential.
- Significant Membership Growth: Cabana Club membership has surpassed 2.65 million, up 39% year-over-year, while ELITE membership reached 178,000, an 84% increase, indicating continued improvement in customer loyalty and market share.
See More
High Tide Reports Strong Q2 Earnings Growth
- Earnings Performance: High Tide reported a non-GAAP EPS of C$0.01 for Q2, indicating a slight improvement in profitability despite the overall turbulent market conditions.
- Revenue Growth: The company achieved revenues of C$179.3 million, reflecting a robust year-over-year increase of 30.1%, showcasing its strong performance in the competitive Canadian cannabis market.
- Cash Position: As of April 30, 2026, High Tide's cash and cash equivalents totaled C$36.5 million, up from C$34.7 million in the prior year, indicating improved financial management.
- Market Challenges: Despite significant revenue growth, the volatility in the cannabis sector remains a concern, necessitating High Tide to navigate market uncertainties to sustain its growth momentum.
See More
High Tide Secures C$40 Million Loan Agreement with BMO
- Loan Agreement Secured: High Tide Inc. has secured a loan agreement with Bank of Montreal for C$40 million in new senior secured credit facilities, with closing expected within 30 days, marking a pivotal moment for the company's growth trajectory.
- Lower Capital Costs: The new credit facilities will replace the existing senior credit facility, which is anticipated to materially lower capital costs, thereby enhancing the company's financial flexibility and supporting future expansion plans.
- Market Share Growth: High Tide's subsidiary, Canna Cabana, operates 228 locations in Canada, capturing a 12% market share, and this financing will facilitate further expansion in global markets, particularly in its retail presence in Germany.
- Recognition of Sustained Growth: High Tide has been recognized as one of Canada's Top Growing Companies for five consecutive years, reflecting its strong performance and market leadership in the rapidly evolving cannabis industry, which is likely to continue attracting investor interest.
See More
High Tide Acquires Northern Helm to Expand Retail Operations
- Acquisition Details: High Tide is acquiring four retail stores from Northern Helm for $7.74 million, which will increase its total store count in Ontario to 103, thereby enhancing its market share and driving revenue growth.
- Strategic Objective: This acquisition represents a significant step towards High Tide's long-term goal of building a network of over 350 stores, demonstrating its commitment and capability in retail market expansion.
- Financial Impact: The purchase price reflects 4.5 times the annualized Adjusted EBITDA of the stores, indicating that High Tide is acquiring cash-flowing assets at reasonable multiples, which is expected to create long-term value for shareholders.
- Diversified Growth: High Tide's medical cannabis division is rapidly emerging as a second engine of growth, further solidifying its competitive advantage in the cannabis industry and driving sustainable growth across its overall business.
See More
